230 related articles for article (PubMed ID: 29611230)
1. In vitro activities of antifungal drugs against environmental Exophiala isolates and review of the literature.
Gülmez D; Doğan Ö; Boral B; Döğen A; İlkit M; de Hoog GS; Arikan-Akdagli S
Mycoses; 2018 Aug; 61(8):561-569. PubMed ID: 29611230
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis.
Sun Y; Liu W; Wan Z; Wang X; Li R
Mycopathologia; 2011 Feb; 171(2):111-7. PubMed ID: 20803255
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.
Duarte AP; Pagnocca FC; Baron NC; Melhem Mde S; Palmeira GA; de Angelis Dde F; Attili-Angelis D
Mycopathologia; 2013 Jun; 175(5-6):455-61. PubMed ID: 23229615
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of amphotericin B, itraconazole, terbinafine and 5-fluocytosine against Exophiala spinifera and evaluation of post-antifungal effects.
Vitale RG; De Hoog GS; Verweij PE
Med Mycol; 2003 Aug; 41(4):301-7. PubMed ID: 12964723
[TBL] [Abstract][Full Text] [Related]
5. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole.
Fothergill AW; Rinaldi MG; Sutton DA
Med Mycol; 2009 Feb; 47(1):41-3. PubMed ID: 19107637
[TBL] [Abstract][Full Text] [Related]
6. Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist.
Badali H; de Hoog GS; Sudhadham M; Meis JF
Med Mycol; 2011 Nov; 49(8):819-24. PubMed ID: 21612562
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of 8 antifungal drugs against 126 clinical and environmental Exophiala isolates.
Najafzadeh MJ; Dolatabadi S; Vicente VA; de Hoog GS; Meis JF
Mycoses; 2021 Nov; 64(11):1328-1333. PubMed ID: 34411353
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs.
Meletiadis J; Meis JF; de Hoog GS; Verweij PE
Mycoses; 2000 Sep; 43(7-8):309-12. PubMed ID: 11036402
[TBL] [Abstract][Full Text] [Related]
9. Species diversity, antifungal susceptibility and phenotypic and genotypic characterisation of Exophiala spp. infecting patients in different medical centres in Brazil.
Silva WC; Gonçalves SS; Santos DW; Padovan AC; Bizerra FC; Melo AS
Mycoses; 2017 May; 60(5):328-337. PubMed ID: 28139861
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
12.
Jia G; Hu J; Tan L; Li L; Gao L; Sun Y
Microbiol Spectr; 2023 Jun; 11(3):e0530222. PubMed ID: 37140396
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility of ocular fungal pathogens recovered from around the world against itraconazole, voriconazole, amphotericin B, and caspofungin.
Ozdemir HG; Oz Y; Ilkit M; Kiraz N
Med Mycol; 2012 Feb; 50(2):130-5. PubMed ID: 21599550
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Effects of Tacrolimus and Azoles against Exophiala dermatitidis.
Gao L; Sun Y; He C; Zeng T; Li M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923863
[No Abstract] [Full Text] [Related]
15. In vitro activities of five antifungal agents against pathogenic Exophiala species.
Li D; Li R; Wang D; Ma S
Chin Med J (Engl); 1999 Jun; 112(6):484-8. PubMed ID: 11601322
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous exophiala species.
Najafzadeh MJ; Saradeghi Keisari M; Vicente VA; Feng P; Shamsian SA; Rezaei-Matehkolaei A; de Hoog GS; Curfs-Breuker I; Meis JF
Antimicrob Agents Chemother; 2013 Dec; 57(12):6395-8. PubMed ID: 24100491
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal susceptibility of Sporothrix globosa isolates from Jilin Province, northeastern China: comparison of yeast and mycelial phases.
Song Y; Li S; Shi Y; Zhao L; Cui Y; Yao L; Zhen Y; Chen R; Cui Y
Braz J Microbiol; 2021 Mar; 52(1):81-90. PubMed ID: 32557246
[TBL] [Abstract][Full Text] [Related]
18. Antifungal susceptibility patterns for Aspergillus, Scedosporium, and Exophiala isolates recovered from cystic fibrosis patients against amphotericin B, and three triazoles and their impact after long-term therapies.
Brito Devoto T; Hermida-Alva K; Posse G; Finquelievich JL; García-Effrón G; Cuestas ML
Med Mycol; 2023 Aug; 61(8):. PubMed ID: 37591630
[TBL] [Abstract][Full Text] [Related]
19. In vitro interactions between 17-AAG and azoles against Exophiala dermatitidis.
Gao L; Sun Y; He C; Li M; Zeng T
Mycoses; 2018 Nov; 61(11):853-856. PubMed ID: 29998564
[TBL] [Abstract][Full Text] [Related]
20. Lonafarnib synergizes with azoles against Aspergillus spp. and Exophiala spp.
Qiao J; Sun Y; Gao L; He C; Zheng W
Med Mycol; 2018 Jun; 56(4):452-457. PubMed ID: 29420769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
